✦ LIBER ✦

Introduction: National institutes of health technology assessment conference on management of temporomandibular disorders

✍ Scribed by James A Lipton

Book ID: 117725925
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 170 KB
Volume: 83
Category: Article
ISSN: 1528-395X
DOI: 10.1016/s1079-2104(97)90090-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

National institutes of health technology

National institutes of health technology assessment conference statement: Management of temporomandibular disorders, April 29–May 1 1996

📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 782 KB

Report on the 55th national institutes o

Report on the 55th national institutes of health consensus conference: Pain management

✍ Laurel Archer Copp 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 103 KB

Bovine Somatotropin and the Safety of Co

Bovine Somatotropin and the Safety of Cows' Milk: National Institutes of Health Technology Assessment Conference Statement

📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 444 KB

National Institutes of Health Consensus

National Institutes of Health Consensus Development Conference: Management of Hepatitis C: 2002

✍ Leonard B. Seeff; Jay H. Hoofnagle 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB

National Institutes of Health consensus

National Institutes of Health consensus development conference statement: Management of hepatitis B

✍ Michael F. Sorrell; Edward A. Belongia; Jose Costa; Ilana F. Gareen; Jean L. Gre 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB

National institutes of health consensus

National institutes of health consensus development conference: Management of hepatitis C: 2002

✍ Leonard B. Seeff; Jay H. Hoofnagle 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB

That conference was prompted by the uncertainty and confusion that surrounded the issues of the natural history, diagnosis, management, and particularly treatment of hepatitis C. At the time, the only available treatment for hepatitis C was monotherapy with interferon alfa. Overall, response rates t